Equities research analysts at HC Wainwright initiated coverage on shares of Equillium (NYSE:EQ) in a research report issued to clients and investors on Friday, AnalystRatings.com reports. The brokerage set a “buy” rating and a $14.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 154.55% from the company’s current price.
Separately, Zacks Investment Research raised Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a research report on Monday, July 8th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Equillium presently has an average rating of “Buy” and a consensus target price of $17.75.
Shares of NYSE:EQ opened at $5.50 on Friday. Equillium has a 52 week low of $5.12 and a 52 week high of $19.69. The firm has a fifty day simple moving average of $5.98.
Equillium (NYSE:EQ) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.04).
A number of hedge funds have recently bought and sold shares of the business. Partner Fund Management L.P. purchased a new stake in Equillium during the fourth quarter valued at about $11,049,000. Victory Capital Management Inc. grew its position in Equillium by 7.4% during the first quarter. Victory Capital Management Inc. now owns 1,323,381 shares of the company’s stock valued at $10,587,000 after acquiring an additional 90,792 shares during the period. FMR LLC purchased a new stake in Equillium during the fourth quarter valued at about $6,994,000. BlackRock Inc. purchased a new stake in Equillium during the fourth quarter valued at about $1,756,000. Finally, Northern Trust Corp purchased a new stake in Equillium during the fourth quarter valued at about $298,000.
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
Read More: Municipal Bonds
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.